Wasman Jane 4

What Happened

• Jane Wasman, a member of Rigel Pharmaceuticals' Board of Directors, was granted 5,750 restricted stock units (RSUs) on 2026-05-15. The grant is reported as an award/acquisition at $0.00 per share (total reported value $0).

Key Details

• Transaction date: 2026-05-15; Filing date: 2026-05-19.
• Transaction type/code: Award/Grant (A).
• Shares granted: 5,750 RSUs; Price per share reported: $0.00; Total reported acquisition value: $0.
• Shares owned after transaction: Not specified in the excerpt provided.
• Footnote: The RSUs will fully vest on the date prior to the company's next Annual Meeting, contingent on Wasman's continuous service on the Board (see F1).
• No 10b5-1 plan, tax-withholding, or late-filing flag was indicated in the provided data.

Context

• This is a grant of restricted stock units (an award), not an open-market purchase or sale. RSU grants are common for directors as compensation and do not require an immediate cash outlay. The shares will only transfer to Wasman upon vesting, per the vesting condition above, so this does not reflect an immediate change in market exposure.